Tempus AI stock rose 0.3% on February 24, 2026. The company announced a partnership with Median Technologies to integrate the FDA-cleared eyonis Lung Cancer Screening software into the Tempus Pixel platform. Earlier in February, Tempus launched a pan-cancer HRD-RNA algorithm designed to identify homologous recombination deficiency across solid tumors, with clinical availability planned for later in 2026. Mizuho initiated coverage with an Outperform rating and $100 price target on February 20. Representative Nancy Pelosi purchased between $50,001 and $100,000 in Tempus AI shares on January 16. CEO Eric Lefkofsky sold approximately $10.5 million worth of stock on February 19 through a trading plan while acquiring 263,430 shares through vested restricted stock units. Analyst sentiment shows 8 Buy ratings, 6 Hold ratings, and 1 Sell rating.
Read full analysisTempus AI stock rose 0.3% on February 24, 2026. The company announced a partnership with Median Technologies to integrate the FDA-cleared eyonis Lung Cancer Screening software into the Tempus Pixel platform. Earlier in February, Tempus launched a pan-cancer HRD-RNA algorithm designed to identify homologous recombination deficiency across solid tumors, with clinical availability planned for later in 2026. Mizuho initiated coverage with an Outperform rating and $100 price target on February 20. Representative Nancy Pelosi purchased between $50,001 and $100,000 in Tempus AI shares on January 16. CEO Eric Lefkofsky sold approximately $10.5 million worth of stock on February 19 through a trading plan while acquiring 263,430 shares through vested restricted stock units. Analyst sentiment shows 8 Buy ratings, 6 Hold ratings, and 1 Sell rating.
Tempus AI is a healthcare technology company that uses artificial intelligence and large-scale genomic data to help physicians make more informed treatment decisions, particularly in oncology and cardiology. The stock rallied roughly 20% last week on a new AI cancer diagnostic algorithm and bullish coverage initiations from Mizuho ($100 target) and Baird ($59 target), then pulled back about 5.5% before stabilizing ahead of today's Q4 2025 earnings report—a high-stakes event given the company's negative GAAP profitability, $10.5 million in recent CEO share sales, and a stock price sitting roughly 45% below its 52-week high.